ALA.AU Arovella Therapeutics Ltd
- Market cap
- AUD 64.1M
- P/E
- -
- P/B
- 4.53x
- ROE
- -48.9%
- Dividend yield
- -
- Fundamental score
- 1.3/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is ALA.AU undervalued?
Graham numberThe Graham number of Arovella Therapeutics Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Arovella Therapeutics Ltd fundamental analysis
6 of 21 checks passedROE 0/2
Low return on equity (-48.9%), below 10%.
ROA 1/1
Return on assets (-46.1%) is above the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (15.9%) is above the industry median (-5.3%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 2/2
Cash covers 2.1 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (4.5x) is above the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Arovella Therapeutics Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Arovella Therapeutics Ltd
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer…
Full company profileArovella Therapeutics Ltd financial statements
Arovella Therapeutics Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 7.22M | 426K | 1.22M | 533K | 257K | 296K | 406K | 17.0K | 136K | - |
| Gross Profit | 1.74M | 240K | 1.02M | 332K | 34.6K | 88.8K | -3.00M | -26.0K | 136K | -118K |
| Operating Income | -1.81M | -6.04M | -2.32M | -3.98M | -2.99M | -7.59M | -9.68M | -10.8M | -11.2M | -11.2M |
| EBITDA | -1.83M | -6.44M | -8.12M | -3.40M | -4.99M | -7.87M | -10.4M | -10.6M | -11.1M | -11.1M |
| Net Income | -1.24M | -5.46M | -7.80M | -9.94M | -5.05M | -8.62M | -10.2M | -8.75M | -7.51M | -6.92M |
| EPS | -0.02 | -0.08 | -0.07 | -0.06 | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 20.0M | 16.6M | 16.3M | 6.71M | 10.7M | 9.21M | 5.47M | 13.3M | 21.6M | 15.0M |
| Total Liabilities | 3.16M | 5.18M | 2.28M | 2.57M | 1.71M | 1.60M | 1.69M | 2.06M | 1.52M | 857K |
| Shareholders' Equity | 16.9M | 11.5M | 14.0M | 4.14M | 8.98M | 7.62M | 3.78M | 11.2M | 20.1M | 14.2M |
| Cash & Short-term Investments | 1.77M | 98.1K | 4.31M | 977K | 6.72M | 6.07M | 5.18M | 12.7M | 20.9M | 14.4M |
| Total Debt | 1.80M | 2.05M | 53.1K | 85.5K | 79.2K | 145K | 145K | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -854K | -2.55M | -2.50M | -2.88M | -3.54M | -6.27M | -6.40M | -6.91M | -6.93M | -6.91M |
| Capital Expenditure | 1.31M | 908K | 1.62M | 388K | 515K | 566K | 2.72K | 129K | 413K | 39.3K |
| Free Cash Flow | -2.16M | -3.46M | -4.12M | -3.27M | -4.06M | -6.83M | -6.40M | -7.04M | -7.34M | -6.95M |
| Ratios | ||||||||||
| ROE | -7.3% | -47.6% | -55.8% | -240.5% | -56.2% | -113.2% | -269.3% | -77.9% | -37.4% | -48.9% |
| ROA | -6.2% | -32.8% | -48.0% | -148.3% | -47.2% | -93.6% | -186.1% | -65.8% | -34.8% | -46.1% |
| Net Profit Margin | -17.1% | -1,281.9% | -639.4% | -1,866.7% | -1,961.3% | -2,914.2% | -2,508.4% | -51,447.3% | -5,521.4% | - |
| Debt to Equity | 0.11x | 0.18x | 0.00x | 0.02x | 0.01x | 0.02x | 0.04x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Arovella Therapeutics Ltd dividends
Arovella Therapeutics Ltd has not paid dividends in the last 10 fiscal years.
Last stock split: 1:25 on Nov 14, 2019.
Who owns Arovella Therapeutics Ltd
- Insiders 23.48%
- Institutions 16.20%
- Public & others 60.33%
- Shares outstanding 1.21B
- Free float 928M
Arovella Therapeutics Ltd company profile
- Company name
- Arovella Therapeutics Ltd
- Ticker
- ALA.AU
- ISIN
- AU0000182784
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- Corporate One, Preston, VIC, Australia, 3072
- Phone
- 61 3 9863 6472
- Website
- arovella.com
About Arovella Therapeutics Ltd
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
Arovella Therapeutics Ltd management
5- Dr. Nicole van der Weerden B.Sc., BSc (Hons), MBA (MBS), Ph.D.Acting Chief Executive Officer
- Mr. Lachie MalliaCFO & Company Secretary
- Ms. Michelle LongSenior Administration Manager
- Dr. Robson DossaSenior Vice President of Manufacturing & Quality
- Dr. Michelle FergusonSenior Director of Research & Development